Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Tuberculosis, PulmonaryTuberculosis Infection
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects
- Conditions
- Cardiac Repolarization
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 6
- Registration Number
- NCT05758818
- Locations
- 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia
Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery
- Conditions
- Cataract
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 68
- Registration Number
- NCT05741632
- Locations
- 🇮🇩
Fakultas Kedokteran Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia
Electrophysiological Effects of Potential QT Prolonging Drugs
- Conditions
- Drug-induced QT ProlongationPharmacokineticsPharmacodynamics
- Interventions
- Drug: Placebo (Part 2)Drug: Placebo (Part 1)
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 44
- Registration Number
- NCT05716854
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT05668936
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
- Conditions
- Healthy Subject
- Interventions
- Drug: Placebo (orelabrutinib tablet simulator)
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05660720
- Locations
- 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, China
The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
- Conditions
- Mixed Bacterial and Fungal KeratitisFungal KeratitisMicrobial KeratitisBacterial Keratitis
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 123
- Registration Number
- NCT05655689
- Locations
- 🇪🇬
Cornea Outpatient Clinic at Alexandria Main University Hospital, Alexandria, Egypt
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05630274
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 94
- Registration Number
- NCT05580003
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇧🇪Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
- Conditions
- Smoking Cessation
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Achieve Life Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT05566288
- Locations
- 🇵🇹
BlueClinical Phase I, Porto, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.